IL-SURGISPHERE
19.3.2020 15:03:10 CET | Business Wire | Press release
As hospitals start to prepare for a surge in confirmed cases of COVID-19, a more pronounced focus will be placed on the appropriate utilization of healthcare resources. Without planning and organization, this surge can lead to delays in care and wasted resources, both of which hurt patients. In conjunction with public health experts, Surgisphere has developed a COVID-19 triage tool that helps prioritize care for patients who are in urgent need of care (https://surgisphere.com/covid-19-triage-tool/ ).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200319005377/en/
Surgisphere leveraged its real time global research network to develop this triage tool. Using its #1 ranked machine learning capabilities, Surgisphere identified the clinical signs and symptoms most predictive of poor outcomes. Using patient age, chronic medical conditions such as cardiovascular disease and diabetes, vital signs, and routine physical exam maneuvers, healthcare professionals on the front line can triage a COVID-19 patient in under a minute.
“This smartphone app will help thousands of vulnerable patients. We have already seen healthcare systems around the world struggling to cope with the extensive number of sick patients. Better triaging them to provide vital healthcare to those who need it the most is a top priority. Our data driven approach combined with advanced machine learning has created a solution that can positively impact healthcare delivery,” said Sapan Desai, MD, PhD, MBA, FACS. Dr. Desai is a vascular surgeon and President and Chief Executive Officer of the Surgisphere Corporation.
This triage tool has been prospectively validated and has a 95.5% overall accuracy. 100% of patients who require immediate attention are correctly triaged. This smartphone app can be accessed at https://www.Surgisphere.com . Surgisphere has also created a COVID-19 mortality risk calculator and diagnosis decision support tool, all freely and immediately available to healthcare professionals around the world.
Surgisphere is currently leveraging its coordinated efforts with global health agencies and its own global network of over 1,200 healthcare organizations to facilitate rapid, world-wide deployment of this life-saving tool. The methodology and results associated with this triage tool have been submitted for peer review and publication in a scientific journal.
Surgisphere is a physician-led company dedicated to making the world a better place, a mission that has motivated its growth and progress since its inception in 2008. An ISO 27001:2013 certified corporation in Chicago, Surgisphere has developed leading solutions in healthcare delivery for patients with kidney disease, cardiovascular disease, lymphedema, and other major diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200319005377/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
